Poseida Therapeutics Accounts Payable

Poseida Therapeutics (PSTX) currently reports a accounts payable of $5.2M as of September 2024. That compares with $2.5M in the prior-year period — up 104.4% year over year. Use the charts on this page to explore Poseida Therapeutics's accounts payable history and peer comparisons.

Poseida Therapeutics's accounts payable increased from $2.5M to $5.2M — a 104.4% year-over-year increase (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Poseida Therapeutics reported $5.2M in accounts payable as of September 2024. That compares with $2.5M in the prior-year period — up 104.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $5.2M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Poseida Therapeutics, and consider following PSTX for alerts when major investors trade the stock.

Poseida Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $5.2M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PSTX with unrelated industries.